Nervonik, Inc., a clinical-stage medical device company developing next-generation peripheral nerve stimulation (PNS) technologies, today announced the closing of an oversubscribed $52.5 million ...

The company will use the funds to accelerate its clinical programs and prepare for commercialization of its neuromodulation ...

Can at-home vagus nerve stimulators deliver on the lofty promises to improve sleep, stress, and anxiety? We tested them and ...

Nervonik announced today that it closed an oversubscribed Series B financing round worth proceeds of $52.5 million.

In another new UAB study, 15 minutes of stimulation before a 45-minute session with a physical therapist made lasting ...

The funds will support further development of Nervonik’s sensing technology and commercialisation of its PNS platform.

The effect size is modest but statistically significant.

Hillsborough, NJ, April 10, 2026 (GLOBE NEWSWIRE)-- This article is for informational purposes only and contains affiliate links. A commission may be earned at no additional cost to the reader if a ...

Nervonik raises $52.5M in Series B funding to advance its peripheral nerve stimulation technology and expand innovative ...

Nervonik Inc. raised $52.5 million in a series B financing round for its peripheral nerve stimulation (PNS) system designed ...

A 2026 product overview of how RevivaFlow Foot is described for burning feet, tingling, and circulation support - covering ...